发明名称 HUMAN PAK65
摘要 A novel humain serine protein kinase, human p21-protein activated serine kinase p65 protein referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.
申请公布号 WO9620948(A1) 申请公布日期 1996.07.11
申请号 WO1996US00487 申请日期 1996.01.05
申请人 ONYX PHARMACEUTICALS, INC. 发明人 ABO, ARIE;MARTIN, GEORGE, A.
分类号 G01N33/566;A61K31/70;A61K38/55;A61P25/00;A61P29/00;A61P35/02;A61P37/00;C12N5/10;C12N9/12;C12N15/09;C12P21/04;G01N33/15;(IPC1-7):C07H21/04;C12N15/00;C12N5/00;C12N1/20 主分类号 G01N33/566
代理机构 代理人
主权项
地址